文献速递临床试验与 GCP

常压氧疗救治急性脑出血脑损伤的安全性与有效性:随机对照试验方案

Safety and efficacy of normobaric oxygenation on rescuing acute intracerebral hemorrhage-mediated brain damage-a protocol of randomized controlled trial.
PubMed 文献 · Trials · 2021-01-26

本研究为随机对照试验方案,计划纳入150例症状发作6小时内经CT确诊的急性自发性脑出血患者,随机分为常压高流量氧疗组与低流量氧疗对照组,比较两组脑灌注、脑水肿、mRS、NIHSS及血浆生物标志物等指标,以评估常压氧疗的安全性和有效性。

要点

  • 常压高流量氧疗方案为8 L/min、每次1小时、每日6次,间歇期2 L/min,共7天。
  • 主要终点为脑出血后第14天及第3个月随访末的mRS。
  • 次要终点包括NIHSS、血浆生物标志物、出血复发率和3个月内死亡率。

核心结论

  • 该研究将为常压氧疗纠正急性脑出血提供初步临床证据,并探讨相关机制。

研究设计与样本

  • 随机对照试验方案,计划纳入150例症状发作6小时内经CT确诊的急性自发性脑出血患者。

关键数值与推荐

  • 常压氧疗组经面罩吸入高流量氧8 L/min、每次1小时、每日6次,间歇期吸入低流量氧2 L/min,共7天。
  • 对照组经面罩仅吸入低流量氧2 L/min,连续7天。
  • 主要终点为脑出血后第14天及第3个月随访末的mRS。
  • 次要终点包括基线及治疗后第1、7、14天的NIHSS和血浆生物标志物,以及第3个月末NIHSS、出血复发率和3个月内死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: All of the existing medication and surgical therapies currently cannot completely inhibit intracerebral hemorrhage (ICH)-mediated brain damage, resulting in disability in different degrees in the involved patients. Normobaric oxygenation (NBO) was reported attenuating ischemic brain injury. Herein, we aimed to explore the safety and efficacy of NBO on rescuing the damaged brain tissues secondary to acute ICH, especially those in the perihematoma area being threatened by ischemia and hypoxia. METHODS: A total of 150 patients confirmed as acute spontaneous ICH by computed tomography (CT) within 6 h after symptoms onset, will enroll in this study after signing the informed consent, and enter into the NBO group or control group randomly according to a random number. In the NBO group, patients will inhale high-flow oxygen (8 L/min, 1 h each time for 6 cycles daily) and intake low-flow oxygen (2 L/min) in intermittent periods by mask for a total of 7 days. While in the control group, patients will breathe in only low-flow oxygen (2 L/min) by mask for 7 consecutive days. Computed tomography and perfusion (CT/CTP) will be used to evaluate cerebral perfusion status and brain edema. CT and CTP maps in the two groups at baseline and day 7 and 14 after NBO or low-flow oxygen control will be compared. The primary endpoint is mRS at both Day14 post-ICH and the end of the 3rd month follow-up. The secondary endpoints include NIHSS and plasma biomarkers at baseline and Day-1, 7, and 14 after treatment, as well as the NIHSS at the end of the 3rd month post-ICH and the incidence of bleeding recurrence and the mortalities within 3 months post-ICH. DISCUSSION: This study will provide preliminary clinical evidence about the safety and efficacy of NBO on correcting acute ICH and explore some mechanisms accordingly, to offer reference for larger clinical trials in the future. TRIAL REGISTRATION: ClinicalTrials.gov NCT04144868 . Retrospectively registered on October 29, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chen Z, Ding J, Wu X, et al. Safety and efficacy of normobaric oxygenation on rescuing acute intracerebral hemorrhage-mediated brain damage-a protocol of randomized controlled trial. Trials. 2021. PMID: 33499916. doi:10.1186/s13063-021-05048-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。